Literature DB >> 7126619

The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease.

O Nilsson, J E Månsson, G Håkansson, L Svennerholm.   

Abstract

Glycolipid changes in spleen autopsy specimens were determined in four cases of Gaucher's disease type I, three cases of type II, and twelve cases of type III. These changes were also determined in liver autopsy specimens from three cases of type II and in nine cases of type III. The concentration of glucosylceramide in spleen was of the same magnitude in all three types, 36.3 +/- 11.7 mmol/kg in type I, 32.7 +/- 8.5 mmol/kg in type II, and 32.6 +/- 6.9 mmol/kg in type III. In liver there were large differences in the glucosylceramide concentration between splenectomized and non-splenectomized cases. Thus, in the non-splenectomized type III cases it was 9.9 +/- 3.0 mmol/kg, while in the splenectomized type III cases it was 24.1 +/- 6.1 mmol/kg. The accelerated deposition of glucosylceramide in liver after splenectomy was also demonstrated by analyses of liver biopsy specimens. A 2-6-fold increase of gangliosides was found in liver and spleen from the three types, with no significant differences between the types. The increase of gangliosides was limited almost exclusively to GM3. Glucosylsphingosine, never detected in normal tissue, was demonstrated in all samples from Gaucher's livers and spleens. The concentration in spleen was in type II, 0.16 +/- 0.05 mmol/kg, in type III, 0.19 +/- 0.05 mmol/kg, while in type I it was significantly lower, 0.07 +/- 0.03 mmol/kg. In liver, the highest concentrations occurred in the splenectomized type III subjects, 0.16 +/- 0.08 mmol/kg, while in the non-splenectomized type III cases it was 0.06 +/- 0.02 mmol/kg and in type II 0.09 +/- 0.02 mmol/kg. The demonstration of high concentrations of the cytotoxic compound glycosylsphingosine may be a contributing factor behind the tissue necrosis and fibrosis commonly seen in spleens and livers from Gaucher's patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7126619     DOI: 10.1016/0005-2760(82)90272-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  A novel assay method for glycosphingolipid deacylase by enzyme-linked immunochemical detection of lysoglycosphingolipid.

Authors:  K Izumi; M T Sawada
Journal:  Lipids       Date:  2001-01       Impact factor: 1.880

Review 2.  The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Authors:  Derralynn A Hughes; Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

3.  Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease.

Authors:  N G Conradi; H Kalimo; P Sourander
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 4.  Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status.

Authors:  K Suzuki
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 5.  Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.

Authors:  J M Aerts; S Van Weely; R Boot; C E Hollak; J M Tager
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease.

Authors:  W M Holleran; E I Ginns; G K Menon; J U Grundmann; M Fartasch; C E McKinney; P M Elias; E Sidransky
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  Selective extraction and effective separation of galactosylsphingosine (psychosine) and glucosylsphingosine from other glycosphingolipids in pathological tissue samples.

Authors:  Yu-Teh Li; Su-Chen Li; Wayne R Buck; Mark E Haskins; Sz-Wei Wu; Kay-Hooi Khoo; Ellen Sidransky; Bruce A Bunnell
Journal:  Neurochem Res       Date:  2010-12-07       Impact factor: 3.996

8.  Niemann-Pick disease type C with enhanced glycolipid storage. Report on further case of so-called lactosylceramidosis.

Authors:  M Elleder; A Jirásek; F Smíd; J Ledvinová; G T Besley; M Stopeková
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

9.  Glucosylsphingosine is a key biomarker of Gaucher disease.

Authors:  Vagishwari Murugesan; Wei-Lien Chuang; Jun Liu; Andrew Lischuk; Katherine Kacena; Haiqun Lin; Gregory M Pastores; Ruhua Yang; Joan Keutzer; Kate Zhang; Pramod K Mistry
Journal:  Am J Hematol       Date:  2016-08-08       Impact factor: 10.047

Review 10.  [Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].

Authors:  K Sandhoff; L Quintern
Journal:  Naturwissenschaften       Date:  1988-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.